Effective Action In Oncology Studies
By Richard Young, Vice President, Vault CDMS
According to Tufts’ latest research on oncology studies, “the number of unplanned substantial amendments made to Phase II and Phase III oncology protocols are 50%-70% higher than observed for other drugs.” Similarly, protocol deviations are higher in oncology trials, especially in Phase II with a mean number of 121.8 deviations vs 75.8 deviations in other areas. Data managers require tools in their EDC that help them respond quickly to the deviations and amendments occurring throughout study execution.
Learn how Vault EDC enables study teams to respond quickly to the deviations and amendments occurring throughout study execution.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.